Basit öğe kaydını göster

dc.contributor.authorYaman, Yöntem
dc.contributor.authorElli, Murat
dc.contributor.authorŞahin, Şifa
dc.contributor.authorÖzdilli, Kürşat
dc.contributor.authorBilgen, Hülya
dc.contributor.authorBayram, Nihan
dc.contributor.authorNepesov, Serdar
dc.contributor.authorAnak, Sema
dc.date.accessioned2021-10-12T07:39:58Z
dc.date.available2021-10-12T07:39:58Z
dc.date.issued2021en_US
dc.identifier.citationYaman, Y., Elli, M., Şahin, Ş., Özdilli, K., Bilgen, H., Bayram, N. ... Anak, S. (2021). Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience. Pediatric Transplantation, 25(5). https://dx.doi.org/10.1111/petr.13962en_US
dc.identifier.issn1397-3142
dc.identifier.issn1399-3046
dc.identifier.urihttps://dx.doi.org/10.1111/petr.13962
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8428
dc.description.abstractDelayed recovery of thrombocytopenia is a well-known complication after allogeneic HSCT. Eltrombopag (ELT), a thrombopoietin receptor agonist (TRAs), induces platelet maturation and release. Mostly conducted in adults, some of the previous studies have shown that ELT seems to enhance platelet recovery for post-allogeneic HSCT thrombocytopenia, appears efficacious, and offers transfusion independence. To evaluate the safety and efficacy of ELT in pediatric patients with prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) after alloHSCT. Retrospective analysis of childhood patients who received treatment with ELT for persistent thrombocytopenia after alloHSCT between May 2016 and August 2019. We evaluated the safety and efficacy of ELT in 18 childhood patients with PIT or SFPR after alloHSCT. Eltrombopag (50 mg/d) treatment was started in all patients, above 6 years of age and 20 kg weight, who had thrombocytopenia despite neutrophil engraftment on the 30th day of HSCT. Our objective was to decrease the need for platelet transfusion and have a platelet count of more than 50 000/mu L. The overall response rate was 77.7%. The median time to achieve a platelet level above 30 000/mu L and 50 000/mu L was 21 and 44 days, respectively. In four patients, platelet count never reached 30 000/mm(3). In two patients, the treatment was discontinued due to grade 3 hepatotoxicity. Our study supports the efficacy and relative safety of ELT use for the treatment of PIT and SFPR seen after alloHSCT in children.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectAlloHSCTen_US
dc.subjectEltrombopagen_US
dc.subjectThrombocytopeniaen_US
dc.titleEltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experienceen_US
dc.typearticleen_US
dc.relation.ispartofPediatric Transplantationen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0002-9710-8653en_US
dc.authorid0000-0002-0476-5452en_US
dc.authorid0000-0002-7129-5024en_US
dc.authorid0000-0002-7424-8688en_US
dc.authorid0000-0002-9688-5223en_US
dc.authorid0000-0002-4551-5433en_US
dc.authorid0000-0001-8489-7449en_US
dc.identifier.volume25en_US
dc.identifier.issue5en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1111/petr.13962en_US
dc.identifier.wosqualityQ4en_US
dc.identifier.scopusqualityQ2en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster